TransCon-TLR-7/8-agonist

N/A

Report date: 2026/01/21 20:00:47
NME

Base Information

Drug NameTransCon-TLR-7/8-agonist
Drug Alias NameTransCon TLR7/8 Agonist
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionToll like receptor 8 agonistsToll like receptor 7 agonistsImmunostimulants +[4] 
TargetsToll like receptor 8Toll like receptor 7Interferon alpha
Therapy Area/IndicationsSolid tumoursHead and Neck NeoplasmsSquamous Cell Carcinoma of Head and Neck +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanPoland +[11] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAscendis Pharma Oncology Division As
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAscendis Pharma Oncology Division AsAscendis Pharma A/S
Active IndicationsN/A
Inactive IndicationsSolid tumoursHead and Neck NeoplasmsSquamous Cell Carcinoma of Head and Neck +[4] 

Other Information

ATC CodeN/A
Related LinksN/A